- Report
- April 2025
- 175 Pages
Global
From €3941EUR$4,490USD£3,409GBP
- Report
- May 2024
- 139 Pages
Global
From €5704EUR$6,499USD£4,935GBP
- Report
- August 2022
- 118 Pages
Global
From €3949EUR$4,500USD£3,417GBP
- Report
- June 2022
- 120 Pages
Global
From €4169EUR$4,750USD£3,607GBP
- Report
- January 2024
- 113 Pages
United States
€3072EUR$3,500USD£2,658GBP
- Report
- March 2023
- 30 Pages
Global
€10751EUR$12,250USD£9,302GBP
Taltz is a biologic drug used to treat moderate to severe plaque psoriasis in adults. It is a human interleukin-17A (IL-17A) inhibitor, which works by blocking the action of IL-17A, a protein that plays a role in the development of psoriasis. Taltz is administered as an injection under the skin, and is typically used in combination with other treatments such as topical medications and phototherapy.
Taltz is one of several biologic drugs used to treat psoriasis, and is one of the most widely prescribed biologics for the condition. It is generally well-tolerated, with the most common side effects being injection site reactions, upper respiratory tract infections, and headache.
The Taltz market is highly competitive, with several major pharmaceutical companies offering biologic drugs for the treatment of psoriasis. These include Eli Lilly, Novartis, AbbVie, Janssen, and Pfizer. Show Less Read more